Neurocrine Biosciences Inc (NASDAQ:NBIX)
| 103.05 Delayed Data As of Oct 15 |  -0.89 / -0.86%Today’s Change | 84.77 Today|||52-Week Range 120.27 | +7.51% Year-to-Date |
Latest NBIX News | Press Releases
No recent news for Neurocrine Biosciences Inc.
Today’s Trading
| Previous close | 104.02 |
| Today’s open | 104.88 |
| Day’s range | 102.73 - 105.25 |
| Volume | 491,976 |
| Average volume (3 months) | 640,158 |
| Market cap | $9.9B |
Data as of 3:59pm ET, 10/15/2021
Growth & Valuation
| Earnings growth (last year) | +983.16% |
| Earnings growth (this year) | -45.99% |
| Earnings growth (next 5 years) | +18.94% |
| Revenue growth (last year) | +32.71% |
| P/E ratio | 27.7 |
| Price/Sales | 8.96 |
| Price/Book | 8.67 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NTLAIntellia Therapeutic... | +1.85 | +1.41% |
| ZLABZai Lab Ltd | +2.04 | +2.06% |
| XLRNAcceleron Pharma Inc | +0.74 | +0.43% |
| CRSPCRISPR Therapeutics ... | +4.05 | +4.21% |
Data as of 5:45pm ET, 10/15/2021
Financials
| Next reporting date | November 2, 2021 |
| EPS forecast (this quarter) | $0.61 |
| Annual revenue (last year) | $1.0B |
| Annual profit (last year) | $407.3M |
| Net profit margin | 38.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
